Viral vectors, such as adenoviruses, play a crucial role in gene therapy and vaccine production, delivering genetic material effectively to target cells. Adenoviral vectors, in particular, offer various advantages, including non-integration into the host genome, high titer growth in cell culture, ease of production, and safety for human applications. However, optimizing the downstream processing (DSP) steps is essential to enhance the yield and infectivity of adenoviral vectors. Factors such as cell lysis methods, incubation conditions, and microfiltration techniques significantly impact the efficiency of the process.
Adenoviral vector production involves upstream and downstream processes. The downstream process, including viral particle release, clarification, and microfiltration, plays a critical role in determining the final product yield. Efficient cell lysis methods, such as repeated freeze-thaw cycles and detergent-based lysis, are essential for releasing viral particles from host cells. Denarase treatment, aimed at reducing host cell DNA contamination, is crucial during cell lysis. The incubation temperature and period during Denarase treatment significantly influence virus purification efficiency but require optimization for maximum yield and stability.
Incubation temperature and period during Denarase treatment impact virus purification efficiency. Optimal conditions for incubation times (ranging from 30 minutes to 4 hours) and temperatures (room temperature to 37°C) are essential for maximizing viral yield. Results suggest that a 2-hour incubation period at 37°C using the Tween-20 detergent lysis method yields the best results in terms of viral genome copies. Understanding the effects of these parameters on vector yield and stabilization is critical for process optimization.
Microfiltration, a crucial step in DSP for removing cell debris and impurities, significantly impacts viral vector yield. Membrane selection, pore size, and material composition influence filtration efficiency. Polyethersulfone (PES) and Surfactant-free Cellulose Acetate (SFCA) membranes are commonly used for microfiltration. Results show that SFCA membranes yield higher viral genome copies compared to PES membranes, emphasizing the importance of membrane selection in optimizing DSP.
The infectivity of the adenoviral vector is another critical parameter affected by cell lysis methods and microfiltration. Immuno-titration assays reveal the impact of incubation conditions on virus infectivity. Results indicate that the infectivity of the vector decreases with increasing temperature, emphasizing the need for careful temperature control during downstream processing. The Denarase enzyme used for reducing host cell DNA does not compromise virus infectivity, highlighting its suitability for DSP.
The study highlights the superiority of the Tween-20 detergent lysis method in enhancing viral yield and infectivity compared to the traditional freeze-thaw method. Optimal conditions include a 2-hour incubation at 37°C for maximum viral genome copies and infectivity. Microfiltration with SFCA membranes proves more efficient in yielding viral genomes, underscoring the importance of membrane selection in DSP. These findings provide valuable insights for optimizing adenoviral vector production processes on an industrial scale, paving the way for improved gene therapy and vaccine development.
Key Takeaways:
– Optimal incubation conditions during Denarase treatment significantly impact adenoviral vector yield and infectivity in downstream processing.
– Membrane selection in microfiltration plays a crucial role in enhancing viral genome copies, with SFCA membranes outperforming PES membranes.
– The Tween-20 detergent lysis method shows superior results in increasing viral yield and infectivity compared to the traditional freeze-thaw method.
– Understanding the effects of incubation temperature, period, and membrane selection is essential for optimizing adenoviral vector production processes.
Tags: cell culture, viral vectors, upstream, chromatography, downstream, filtration, clinical trials, vaccine production, gene therapy, bioprocess
Read more on pmc.ncbi.nlm.nih.gov